Literature DB >> 31389309

Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists.

Rohit A Sinha1, Eveline Bruinstroop2,3, Brijesh K Singh2, Paul M Yen2,4.   

Abstract

Background: Thyroid hormones (THs) exert a strong influence on mammalian lipid metabolism at the systemic and hepatic levels by virtue of their roles in regulating circulating lipoprotein, triglyceride (TAG), and cholesterol levels, as well as hepatic TAG storage and metabolism. These effects are mediated by intricate sensing and feedback systems that function at the physiological, metabolic, molecular, and transcriptional levels in the liver. Dysfunction in the pathways involved in lipid metabolism disrupts hepatic lipid homeostasis and contributes to the pathogenesis of metabolic diseases, such as nonalcoholic fatty liver disease (NAFLD) and hypercholesterolemia. There has been strong interest in understanding and employing THs, TH metabolites, and TH mimetics as lipid-modifying drugs. Summary: THs regulate many processes involved in hepatic TAG and cholesterol metabolism to decrease serum cholesterol and intrahepatic lipid content. TH receptor β analogs designed to have less side effects than the natural hormone are currently being tested in phase II clinical studies for NAFLD and hypercholesterolemia. The TH metabolites, 3,5-diiodo-l-thyronine (T2) and T1AM (3-iodothyronamine), have different beneficial effects on lipid metabolism compared with triiodothyronine (T3), although their clinical application is still under investigation. Also, prodrugs and glucagon/T3 conjugates have been developed that direct TH to the liver. Conclusions: TH-based therapies show clinical promise for the treatment of NAFLD and hypercholesterolemia. Strategies for limiting side effects of TH are being developed and may enable TH metabolites and analogs to have specific effects in the liver for treatments of these conditions. These liver-specific effects and potential suppression of the hypothalamic/pituitary/thyroid axis raise the issue of monitoring liver-specific markers of TH action to assess clinical efficacy and dosing of these compounds.

Entities:  

Keywords:  NAFLD; analogs; cholesterol; metabolites; thyroid hormone

Mesh:

Substances:

Year:  2019        PMID: 31389309      PMCID: PMC6850905          DOI: 10.1089/thy.2018.0664

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  162 in total

Review 1.  Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism.

Authors:  Rohit A Sinha; Brijesh K Singh; Paul M Yen
Journal:  Trends Endocrinol Metab       Date:  2014-08-12       Impact factor: 12.015

2.  3,5-Diiodo-L-thyronine modulates the expression of genes of lipid metabolism in a rat model of fatty liver.

Authors:  Elena Grasselli; Adriana Voci; Ilaria Demori; Laura Canesi; Rita De Matteis; Fernando Goglia; Antonia Lanni; Gabriella Gallo; Laura Vergani
Journal:  J Endocrinol       Date:  2011-11-22       Impact factor: 4.286

3.  Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist.

Authors:  Rebecca Taub; Edward Chiang; Malorie Chabot-Blanchet; Martha J Kelly; Richard A Reeves; Marie-Claude Guertin; Jean-Claude Tardif
Journal:  Atherosclerosis       Date:  2013-08-21       Impact factor: 5.162

4.  Association between thyroid function and nonalcoholic fatty liver disease in euthyroid elderly Chinese.

Authors:  Chengfu Xu; Lei Xu; Chaohui Yu; Min Miao; Youming Li
Journal:  Clin Endocrinol (Oxf)       Date:  2011-08       Impact factor: 3.478

5.  Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist.

Authors:  Edward E Cable; Patricia D Finn; Jeffrey W Stebbins; Jinzhao Hou; Bruce R Ito; Paul D van Poelje; David L Linemeyer; Mark D Erion
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

6.  Human spot 14 glucose and thyroid hormone response: characterization and thyroid hormone response element identification.

Authors:  Mark C Campbell; Grant W Anderson; Cary N Mariash
Journal:  Endocrinology       Date:  2003-08-21       Impact factor: 4.736

7.  Comparative efficacy and side effects of the treatment of euthyroid goiter with levo-thyroxine or triiodothyroacetic acid.

Authors:  G Brenta; M Schnitman; O Fretes; E Facco; M Gurfinkel; S Damilano; N Pacenza; A Blanco; E Gonzalez; M A Pisarev
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

Review 8.  Transcriptional regulation of hepatic lipogenesis.

Authors:  Yuhui Wang; Jose Viscarra; Sun-Joong Kim; Hei Sook Sul
Journal:  Nat Rev Mol Cell Biol       Date:  2015-11       Impact factor: 94.444

9.  TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats.

Authors:  Shitalkumar P Zambad; Siralee Munshi; Amita Dubey; Ram Gupta; Rosa Anna Busiello; Antonia Lanni; Fernando Goglia; Ramesh C Gupta; Vijay Chauthaiwale; Chaitanya Dutt
Journal:  Diabetes Metab Syndr Obes       Date:  2011-01-06       Impact factor: 3.168

10.  The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice.

Authors:  Ivan Tancevski; Egon Demetz; Philipp Eller; Kristina Duwensee; Julia Hoefer; Christiane Heim; Ursula Stanzl; Andreas Wehinger; Kristina Auer; Regina Karer; Julia Huber; Wilfried Schgoer; Miranda Van Eck; Jonathan Vanhoutte; Catherine Fievet; Frans Stellaard; Mats Rudling; Josef R Patsch; Andreas Ritsch
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

View more
  46 in total

Review 1.  Therapeutic pipeline in nonalcoholic steatohepatitis.

Authors:  Raj Vuppalanchi; Mazen Noureddin; Naim Alkhouri; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-10       Impact factor: 46.802

2.  Vitamins and non-alcoholic fatty liver disease: A Molecular Insight.

Authors:  Sana Raza; Archana Tewari; Sangam Rajak; Rohit A Sinha
Journal:  Liver Res       Date:  2021-04-04

Review 3.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

Review 4.  Environmental Toxicants and NAFLD: A Neglected yet Significant Relationship.

Authors:  Sangam Rajak; Sana Raza; Archana Tewari; Rohit A Sinha
Journal:  Dig Dis Sci       Date:  2021-08-12       Impact factor: 3.487

5.  Effects of Different Green Teas on Obesity and Non-Alcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice.

Authors:  Dan-Dan Zhou; Qian-Qian Mao; Bang-Yan Li; Adila Saimaiti; Si-Yu Huang; Ruo-Gu Xiong; Ao Shang; Min Luo; Hang-Yu Li; Ren-You Gan; Hua-Bin Li; Sha Li
Journal:  Front Nutr       Date:  2022-06-24

6.  Mediation effects of thyroid function in the associations between phthalate exposure and lipid metabolism in adults.

Authors:  Han-Bin Huang; Po-Keng Cheng; Chi-Ying Siao; Yuan-Ting C Lo; Wei-Chun Chou; Po-Chin Huang
Journal:  Environ Health       Date:  2022-07-01       Impact factor: 7.123

Review 7.  Life Without Thyroid Hormone Receptor.

Authors:  Yun-Bo Shi
Journal:  Endocrinology       Date:  2021-04-01       Impact factor: 4.736

Review 8.  Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease.

Authors:  Ronan Thibaut; Matthew C Gage; Inès Pineda-Torra; Gwladys Chabrier; Nicolas Venteclef; Fawaz Alzaid
Journal:  FEBS J       Date:  2021-05-02       Impact factor: 5.622

Review 9.  Current treatment paradigms and emerging therapies for NAFLD/NASH.

Authors:  Sana Raza; Sangam Rajak; Aditya Upadhyay; Archana Tewari; Rohit Anthony Sinha
Journal:  Front Biosci (Landmark Ed)       Date:  2021-01-01

10.  Association Between Thyroid Hormone Levels and Advanced Liver Fibrosis in Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.

Authors:  Jing Du; Sanbao Chai; Xin Zhao; Jianbin Sun; Xiaomei Zhang; Lili Huo
Journal:  Diabetes Metab Syndr Obes       Date:  2021-05-26       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.